Simplify Logo

Full-Time

Senior Director

Manufacturing

Posted on 6/27/2024

ElevateBio

ElevateBio

201-500 employees

Develops and manufactures cell and gene therapies

Hardware
Industrial & Manufacturing
Biotechnology

Expert

Waltham, MA, USA

Category
Manufacturing Engineering
Mechanical Engineering
Requirements
  • Minimum Bachelor’s Degree in Engineering, Biotech, Supply Chain, or related field
  • At least 15 years of experience in a Manufacturing, Technical Operations, or GMP environment supporting complex products. Experience in autologous gene or cell therapy a plus.
  • Direct oversight and experience leading in a commercial manufacturing team required. Direct oversight and leadership of teams > 30 FTEs and over multiple shifts strongly preferred.
  • Experience working within a contract manufacturing or client service organization strongly preferred.
  • Familiarity with manufacturing architectures and systems (e.g. SAP, electronic batch records)
  • Demonstrated ability and strength in leading cross-functional teams within a matrixed organization.
Responsibilities
  • Lead department to ensure consistent, reliable, timely and compliant manufacturing of products across all modalities at the site spanning clinical and commercial phases.
  • Effectively partner with Quality, Facilities and Engineering, Supply Chain, and other functions to maintain procedures and processes for timely release of all manufactured products.
  • Develop and maintain training records, operating procedures, and policies in accordance with Current Good Manufacturing Practices.
  • Collaborate with process development and other subject matter experts to support internal and partner technology transfers into manufacturing.
  • Develop short- and long-term goals for the department in accordance with overall corporate and site objectives. Create, measure, trend, and report manufacturing related KPIs as a basis to drive continuous improvement.

ElevateBio focuses on biotechnology, specifically in the cell and gene therapy market. They use proprietary technologies like gene editing and induced pluripotent stem cells (iPSC) to develop and manufacture therapies. Their integrated ecosystem allows them to support the entire process from discovery to commercialization, setting them apart from competitors. The goal is to advance scientific breakthroughs and deliver a wide range of effective therapies.

Company Stage

Series D

Total Funding

$1.2B

Headquarters

Waltham, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

4%

1 year growth

1%

2 year growth

15%
Simplify Jobs

Simplify's Take

What believers are saying

  • ElevateBio's recent $401 million Series D financing round, led by prominent investors, positions the company for accelerated growth and innovation.
  • The collaboration with the University of Pittsburgh to build the BioForge facility will significantly expand their manufacturing capabilities and technological infrastructure.
  • Their partnerships and commercialization efforts, including potential earnouts up to $2.35 billion with Novo Nordisk, offer substantial financial and developmental opportunities.

What critics are saying

  • The highly competitive biotechnology sector requires continuous innovation and investment to maintain a leading position.
  • Dependence on strategic partnerships and collaborations may pose risks if these relationships encounter challenges or fail to deliver expected outcomes.

What makes ElevateBio unique

  • ElevateBio's integrated ecosystem of technologies and capabilities allows them to discover, develop, manufacture, and commercialize a broad spectrum of cell and gene therapies, setting them apart from competitors who may only focus on one aspect of the process.
  • Their strategic partnerships with industry leaders like Novo Nordisk and Kyverna Therapeutics enhance their technological and therapeutic development capabilities.
  • The company's proprietary technologies, such as gene editing and induced pluripotent stem cell (iPSC) platforms, provide a competitive edge in the biotechnology market.
INACTIVE